Global Market Bulletin
  • Home
  • Stock Market News
  • Investing
  • Economy
  • CEO Interviews
  • Contact Us
No Result
View All Result
SUBSCRIBE
Global Market Bulletin
  • Home
  • Stock Market News
  • Investing
  • Economy
  • CEO Interviews
  • Contact Us
No Result
View All Result
Global Market Bulletin
No Result
View All Result
Home Stock Market News

Apple CEO Tim Cook Receives $750 Million in AAPL Stock According to SEC Form 4 Filing

by Global Market Bulletin
August 27, 2021
in Stock Market News
0
Apple CEO Tim Cook Receives $750 Million in AAPL Stock According to SEC Form 4 Filing
39
SHARES
84
VIEWS
Share on FacebookShare on Twitter

This week, Apple CEO Tim Cook received over five million shares of his company’s stock. The total value of stock received was more than $750 Million USD.

You might also like

Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?

Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?

Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

AAPL Tim Cook SEC Form 4 Filing – 8/24/21

As part of his 2011 agreement, Cook received stock based on how Apple’s performance compared to other companies in the S&P 500.

Cook is being compensated with the final part of the stock package when he became CEO of Apple ten years ago.

Since Cook became CEO in 2011, Apple stock has risen over 1200%.

In 2020, Cook received a new compensation package that will run through 2026.

The majority of Tim Cook’s compensation is in the form of AAPL stock restricted units.

According to the filing, Apple ranked 13th out of 442 companies in the cohort with a total shareholder return of 191.83%, which was within the top third.

He previously said he will donate his entire fortune to charity and continued to enforce that statement by donating $10 Million worth of Apple stock earlier this week in a SEC filing.

Tags: Apple Stock - AAPLSEC Form 4 FilingTim Cook
Share16Tweet10

Global Market Bulletin

Global Market Bulletin is a leading provider of stock market updates, economic news, and personalized investing guides. Our team brings you the latest global financial information to help you make smart investment decisions. About the Editorial Team Our editorial team consists of financial experts and seasoned market analysts who bring decades of experience to our coverage. With a commitment to unbiased reporting, our team ensures that every article is backed by thorough research and delivers accurate financial insights.

Recommended For You

Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?

by Global Market Bulletin
July 18, 2026
0
Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?

by Global Market Bulletin
July 18, 2026
0
Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

by Global Market Bulletin
July 18, 2026
0
Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

What Makes SharpLink (SBET) a High-Risk Stock Investors Cannot Ignore?

by Global Market Bulletin
July 18, 2026
0
What Makes SharpLink (SBET) a High-Risk Stock Investors Cannot Ignore?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Is Omeros (OMER) a Smart Biotech Investment Before Its Next Major Catalyst?

by Global Market Bulletin
July 18, 2026
0
Is Omeros (OMER) a Smart Biotech Investment Before Its Next Major Catalyst?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Browse by Category

  • CEO Interviews
  • Economy
  • Investing
  • Stock Market News
  • Uncategorized

QUICK LINKS

  • Stock Market News
  • Investing
  • Economy
  • Contact Us
  • About Global Market Bulletin
  • Editorial Policy – Global Market Bulletin
  • Our Editorial Team

RECENT POSTS

  • Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?
  • Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?
  • Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

GET EMAIL MARKET UPDATES

Subscribe to our mailing list to receives daily updates direct to your inbox!
  • Privacy Policy
  • Terms and Conditions

© 2022 Global Market Bulletin. All Rights Reserved.

No Result
View All Result
  • Home
  • Stock Market News
  • Investing
  • Economy

© 2022 Global Market Bulletin. All Rights Reserved.

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?